Table 3.
Decision tree based on various methods, clinical features and demographic characteristics
| Decision tree | Conditional attribute | Predicted antibody (probability) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Psychiatric | SPS spectrum | Ataxia | Dyskinesia | Opsoclonus | Chorea/choreoathetosis | Dystonia | Age | Disease duration | ||
| Unsupervised method based on clinical feature only | 0 | 0 | 1 | 0 | GAD (0.47) | |||||
| 0 | 1 | GAD (0.67) | ||||||||
| 0 | 0 | 1 | 1 | ANNA-2/Ri (0.68) | ||||||
| 1 | NMDAR (0.71) | |||||||||
| 0 | 0 | 0 | 1 | NMDAR (0.87) | ||||||
| 0 | 0 | 0 | 0 | 1 | CRMP5/CV2 (0.41) | |||||
| Supervised method based on clinical features only | 0 | 1 | 0 | 0 | GAD (0.42) | |||||
| 1 | 0 | GAD (0.61) | ||||||||
| 0 | 1 | 0 | 1 | ANNA-2/Ri (0.40) | ||||||
| 1 | NMDAR (0.92) | |||||||||
| Unsupervised method based on clinical features and demographic characteristics | 1 | ≥ 37 | GAD (0.65) | |||||||
| 0 | 1 | < 37 | GAD (0.76) | |||||||
| 1 | 0 | 0 | ≥ 37 | < 0.23 | NMDAR (0.38) | |||||
| 1 | 1 | < 37 | NMDAR (0.58) | |||||||
| 1 | 0 | 0 | ≥ 37 | ≥ 0.23 | LGI-1 (0.47) | |||||
| 0 | 1 | ≥ 37 | IgLON5 (0.42) | |||||||
| Supervised method based on clinical features and demographic characteristics | 0 | 1 | 0 | ≥ 37 | GAD (0.44) | |||||
| 1 | ≥ 37 | GAD (0.65) | ||||||||
| 0 | 1 | < 37 | GAD (0.76) | |||||||
| 1 | 1 | < 37 | NMDAR (0.52) | |||||||
| 0 | 0 | 1 | ≥ 37 | < 0.05 | CRMP5/CV2 (0.53) | |||||
| 0 | 1 | 1 | ≥ 37 | IgLON5 (0.67) | ||||||